These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34572302)

  • 21. In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector.
    Roy S; Shirley PS; Connelly S; Andrews JL; Kayda DB; Gardner JM; Kaleko M
    Haemophilia; 1999 Sep; 5(5):340-8. PubMed ID: 10583516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
    Front Immunol; 2020; 11():1293. PubMed ID: 32670285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical gene transfer studies for hemophilia A.
    Chuah MK; Collen D; VandenDriessche T
    Semin Thromb Hemost; 2004 Apr; 30(2):249-56. PubMed ID: 15118936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.
    Li YJ; Chen C; Zeng LY; Cao J; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
    Zhu F; Liu Z; Miao J; Qu H; Chi X
    Sci China Life Sci; 2012 Jun; 55(6):521-6. PubMed ID: 22744182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles.
    Chen CY; Tran DM; Cavedon A; Cai X; Rajendran R; Lyle MJ; Martini PGV; Miao CH
    Mol Ther Nucleic Acids; 2020 Jun; 20():534-544. PubMed ID: 32330871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
    Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioengineering of coagulation factor VIII for improved secretion.
    Miao HZ; Sirachainan N; Palmer L; Kucab P; Cunningham MA; Kaufman RJ; Pipe SW
    Blood; 2004 May; 103(9):3412-9. PubMed ID: 14726380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A.
    Kumar P; Gao K; Wang C; Pivetti C; Lankford L; Farmer D; Wang A
    Cell Transplant; 2018 Jan; 27(1):130-139. PubMed ID: 29562772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction.
    Sun J; Chen X; Chai Z; Niu H; Dobbins AL; Nichols TC; Li C
    Front Med (Lausanne); 2022; 9():880763. PubMed ID: 35991645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. piggyBac-mediated phenotypic correction of factor VIII deficiency.
    Staber JM; Pollpeter MJ; Arensdorf A; Sinn PL; Rutkowski DT; McCray PB
    Mol Ther Methods Clin Dev; 2014; 1():14042. PubMed ID: 26015980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FVIII gene delivery by muscle electroporation corrects murine hemophilia A.
    Long YC; Jaichandran S; Ho LP; Tien SL; Tan SY; Kon OL
    J Gene Med; 2005 Apr; 7(4):494-505. PubMed ID: 15521095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
    Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB
    Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.
    Shetty KA; Merricks EP; Raymer R; Rigsbee N; Nichols TC; Balu-Iyer SV
    J Pharm Sci; 2016 Aug; 105(8):2459-64. PubMed ID: 27372547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.
    Wang X; Fu RY; Li C; Chen CY; Firrman J; Konkle BA; Zhang J; Li L; Xiao W; Poncz M; Miao CH
    Blood Adv; 2020 Nov; 4(22):5722-5734. PubMed ID: 33216891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.
    Samelson-Jones BJ; Arruda VR
    Mol Ther Methods Clin Dev; 2019 Mar; 12():184-201. PubMed ID: 30705923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular genetics of hemophilia A].
    De Brasi CD; Slavutsky IR; Larripa IB
    Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerating Factor VIII: Recent Progress.
    Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
    Front Immunol; 2019; 10():2991. PubMed ID: 31998296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
    Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
    Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.